NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 1259M 
Neuropharm Group PLC 
18 May 2010 
 

 
+------------------------------------+------------------------------+ 
| For immediate release              |                  18 May 2010 | 
+------------------------------------+------------------------------+ 
 
 
 
                              Neuropharm Group Plc 
                        ("Neuropharm" or "the Company") 
 
                            Result of General Meeting 
 
Neuropharm Group plc (AIM: NPH) confirms that, at the General Meeting held 
earlier today, the Resolution set out in the circular sent to shareholders on 20 
April 2010 to effect a winding up of the Company by way of a members' voluntary 
liquidation ("MVL") and the cancellation of admission to trading of the 
Company's securities on AIM was duly passed. Cancellation of admission is 
therefore expected to occur at 7.00 a.m. tomorrow, 19 May 2010. The result of 
the GM was 21,975,056 votes in favour of the Resolution, no votes against and no 
abstentions. 
 
Following the General Meeting, the appointment of Samantha Jane Keen and Ian 
Carr of Grant Thornton UK LLP, No 1 Dorset Street, Southampton SO15 2DP as joint 
liquidators of the Company (the "Liquidators") is now effective. The Liquidators 
will be responsible for dealing with the conduct of the MVL and the 
determination of the timing and amount of any distribution(s) to Shareholders. A 
Q&A relating to the liquidation process will be posted on the Company's website 
at www.neuropharm.co.uk. 
 
 
For further information please contact: 
+----------------------------------------+----------------+ 
| Neuropharm                             | + 44 (0) 1372  | 
|                                        | 371 171        | 
+----------------------------------------+----------------+ 
| Robert Mansfield, Chief Executive      |                | 
| Officer                                |                | 
| Graham Yeatman, Chief Financial        |                | 
| Officer                                |                | 
+----------------------------------------+----------------+ 
|                                        |                | 
+----------------------------------------+----------------+ 
| Grant Thornton UK LLP                  | +44 (0) 2380   | 
| Samantha Keen                          | 381 100   + 44 | 
| Ian Carr Piper Jaffray Ltd.            | (0) 20 3142    | 
|                                        | 8700           | 
+----------------------------------------+----------------+ 
| Neil Mackison, Rupert Winckler         |                | 
+----------------------------------------+----------------+ 
|                                        |                | 
+----------------------------------------+----------------+ 
 
Notes to Editors: 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 ROMLVLFFBEFLBBZ 
 

Neuropharm (LSE:NPH)
Historical Stock Chart
From Nov 2024 to Dec 2024

Neuropharm (LSE:NPH)
Historical Stock Chart
From Dec 2023 to Dec 2024